In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: Interindividual variation and increased platelet secretion

Haematologica

Volumn 86, Issue 2, 2001, Pages 192-198

  Rossi, F ^a   Rossi, E ^a   Pareti, F I ^a   Colli, S ^a   Tremoli, E ^a   Gallo, L ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Abciximab; Flow cytometry; Glycoprotein IIb IIIa; P selectin; Platelets

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR;

ARTICLE; DRUG MECHANISM; DRUG RECEPTOR BINDING; FLOW CYTOMETRY; HUMAN; NORMAL HUMAN; SHEAR STRESS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION;

ADULT; ANTIBODIES, MONOCLONAL; BLOOD PLATELETS; CELL DEGRANULATION; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX;

EID: 0035107399     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Pathogenesis of thrombosis
2. New antiplatelet agents: Platelet GPIIb/IIIa antagonists
3. Novel antiplatelet therapies for treatment of patients with ischemic heart disease: Inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor
4. Advancing the battle against acute ischemic syndromes: A focus on the GP IIb/IIIa inhibitors
5. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes
6. Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty
7. Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
8. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months. The EPIC Investigators
9. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy
10. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
11. An overview of platelet GPIIb/IIIa receptor antagonists trial
12. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention
13. Standard versus low dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators
14. Expression of markers of platelet activation and the interpatient variation in response to abciximab
15. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb-IIIa receptors
16. Intensity of inhibition of the platelet glycoprotein IIb/IIIa receptor differs among disease states
17. A murine glycoprotein lb complex monoclonal antibody, SZ 2, inhibits platelet aggregation induced by both ristocetin and collagen
18. Redistribution of α-granule membrane glycoprotein IIb/IIIa (integrin αIIβb3) to the surface of human platelets during the release reaction
19. A monoclonal antibody against the platelet fibrinogen receptor contains a sequence that mimics a receptor recognition domain in fibrinogen
20. Analysis of platelet aggregation disorders based on flow cytometry analysis of membrane glycoprotein IIb-IIIa with conformation-specific monoclonal antibodies
21. Evaluation of the abnormal platelet function in von Willebrand disease by the blood filtration test
22. Paradoxical inhibition of fibrinogen binding and potentiation of α-granule release by specific types of inhibitors of glycoprotein IIb-IIIa
23. Dissociation between the anti-aggregatory and anti-secretory effects of platelet integrin αIIβb3 (GPIIb/IIIa) antagonists, c7E3 and DMP728
24. Increased reactivity of platelets induced by fibrinogen independent of its binding to the IIb-IIIa surface glycoprotein: Potential contributor to cardiovascular risk
25. Molecular mechanisms of leukocyte recruitment in the inflammatory process
26. Platelet-endothelial cell interactions during ischemia/reperfusion: The role of P-selectin
27. c7E3Fab reduces postischemic leukocyte-thrombocyte interaction mediated by fibrinogen. Implications for myocardial reperfusion injury
28. Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction